When Quality Systems Fail: What a GLP-1 Warning Letter Reveals Mar 6, 2026

On January 16, 2026, the FDA issued a warning letter to Boothwyn Pharmacy LLC, a compounding pharmacy in Kennett Square, Pennsylvania that produces semaglutide and tirzepatide injectables—the active ingredients in Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. The letter followed an inspection from May to June 2025.

This is not a story about paperwork. It’s a story about what happens when a quality system exists on paper but fails in practice and patients bear the consequences.

What the FDA Found

The inspection documented four interlocking failures:

• No sterile environmental control. Smoke studies showed turbulent airflow in critical manufacturing zones. Surfaces were porous and difficult to clean. A post-inspection cleanroom remodel was completed without updated certification or environmental monitoring data.
• Subpotent and non-sterile products released to patients. Semaglutide tested at ~80% of labeled potency. Tirzepatide lots tested at ~85% and ~90%. One tirzepatide lot failed sterility testing entirely. All of these products reached patients.
• OOS investigations that didn’t follow the firm’s own procedures. The FDA reviewed 23 out-of-specification investigation reports from a seven-month window. Not one followed the firm’s written SOP. Not one documented patient notification. Nineteen remained open at the time of inspection.
• Contradictory batch release SOPs. One section required sterility results before release; another permitted release without them. A separate SOP allowed “at risk” release without specifying whether patients would be notified if the product later failed sterility testing.

Patients received injectable medications their pharmacy’s own lab identified as subpotent or non-sterile and were never told.

Why It Matters Beyond This One Pharmacy

Compounded GLP-1 drugs have become one of the most contested regulatory issues in the industry. Branded manufacturers have argued that compounded versions produced outside the CGMP framework carry unacceptable safety risks. Compounding advocates have countered that quality concerns are overstated. This warning letter gives the first camp a concrete, documented example to point to—and it’s already expected to appear in regulatory filings, litigation, and congressional testimony.

Three Takeaways for Quality Professionals

1. SOPs that aren’t followed may be worse than no SOPs. Written procedures create a documented expectation of compliance. When an investigator finds zero of 23 investigations followed the firm’s own procedure, that’s not just an execution failure; it’s a management oversight failure. Someone signed off on those investigations.

2. Releasing “at risk” without follow-through isn’t risk management; it’s liability transfer. Early release of sterile products is only defensible when paired with rigorous tracking and patient notification. Without those controls, the risk doesn’t get managed. It gets handed to the patient.

3. Root cause analysis isn’t optional. The FDA noted that the firm’s corrective action responses never identified why the sterility and potency failures occurred. Corrective actions that skip root cause don’t prevent recurrence. They just defer the next failure.

Read more about the FDA 483 process at the link below.

The FDA 483 Isn’t the Risk. The Response Is.

REFERENCES

1. FDA Warning Letter — Boothwyn Pharmacy LLC, No. 717525 (Jan. 16, 2026)

2. FDA — Compounding Inspections, Recalls, and Other Actions

3. FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

4. FDA Guidance — Sterile Drug Products Produced by Aseptic Processing (2004)